-

Afrin® WOWs Parents with Launch of Children’s Acute Medicated Nasal Sprays – Because One Sick Kid Can Throw Everything Off in An Instant

Children’s Afrin® products provide ridiculously FAST nasal congestion relief, so busy parents can get their families back on track. The WOW is REAL!

WHIPPANY, N.J.--(BUSINESS WIRE)--Afrin®, the #1 doctor and pharmacist recommended nasal spray brand1, announced today the launch of Children’s Afrin®, the children's acute medicated nasal spray that works fast and lasts up to 12 hours. Available in retail stores nationwide, the line of children’s medicated consumer products includes Afrin® Extra Moisturizing Stuffy Nose Spray and Afrin® No Drip Extra Moisturizing Stuffy Nose Spray.

Children’s Afrin® provides targeted fast relief, for children who suffer from nasal congestion due to colds or allergies. The children’s medicated product line offers nasal spray products for children two to six and six and up:

  • Afrin® Extra Moisturizing Stuffy Nose Pump Mist, for ages two to six years old, is specially formulated for young children and unblocks a stuffy nose fast
  • Afrin® No Drip Extra Moisturizing Stuffy Nose Pump Mist, for ages six years old and up, targets nasal congestion in seconds without dripping down the nose or throat

“There’s nothing worse than when you’re almost out the door, and your child runs over with their stuffy and snotty nose complaining of being sick because you know your plans for the day have been thwarted. That’s why we’re excited to bring the power of Afrin’s fast congestion relief to the whole family, so all ages can breathe more freely,” said Catherine Vennat, VP/GM, Upper Respiratory, Bayer Consumer Health U.S. “Children suffering from colds or allergies now have access to nasal congestion relief that works fast and allows children to feel like themselves again, and their busy parents to get their families back on track while juggling multiple responsibilities.”

The nasal sprays offer fast relief to children for up to 12 hours, providing comfort to children and their parents, all day or all night. Children’s Afrin® Medicated Nasal Sprays are available at mass retail locations. For more information, please visit https://www.afrin.com/ or follow us on Instagram and Twitter.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

1 Pharmacy Times Survey 2020

Contacts

Danielle Goonan
Senior Director, Strategic Communications, Brand PR, Influencer & Social, Bayer Consumer Health U.S.
danielle.goonan@bayer.com

Bayer


Release Versions

Contacts

Danielle Goonan
Senior Director, Strategic Communications, Brand PR, Influencer & Social, Bayer Consumer Health U.S.
danielle.goonan@bayer.com

More News From Bayer

Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that one late-breaking presentation along with five posters across its cardiovascular programs will be featured at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Phoenix, Arizona, from October 9-12, 2026. Key Facts A post-hoc analysis from the Phase III REVEAL study, which evaluated the investigational PET radiotracer I 124 evuzamitide for the sensitivity and specificity of cardiac amyloidosis based o...

Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet® (elinzanetant) 60mg capsules, Bayer’s FDA-approved, hormone-free prescription treatment for moderate to severe hot flashes due to menopause.1 Through the partnership, Hart will share her personal experience with moderate to severe hot flashes due to menopause to help women recognize their symptoms and to encourage more proactive treatmen...

U.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company’s supplemental New Drug Application (sNDA) for KERENDIA® (finerenone), which is being investigated for the treatment of adults with chronic kidney disease (CKD) without diabetes who are receiving background standard of care. Key Facts The sNDA was supported by results from the Phase III FIND-CKD trial investigating KERENDIA in adults with CKD without diabete...
Back to Newsroom